Panagene licenses right to sell PNAs from CIG
Daejeon, South Korea-based Panagene has licensed the right to sell peptide nucleic acid monomers from the Copenhagen Inventor Group. The agreement allows the firm to synthesize, manufacture and sell PNA monomers for use by researchers. Panagene had previously obtained an exclusive worldwide license under CIG's patents to PNA custom synthesis.
PNAs are mimics of DNA with unique properties that confer advantages in many applications. Panagene estimates the PNA market today to be approximately 5% of DNA/RNA synthesis sector but, with this license, strongly believes that it will be able to grow this significantly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze